Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × apalutamide × Clear all

Phase

Phase 2 11 Phase 3 7 Phase 1 2 Phase NA 1 Phase 2/3 1 Phase 1/2 1

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 109 Cyclophosphamide 79 fludarabine 59 Carboplatin 59 Injections 58 Bevacizumab 51 Gemcitabine 41 Specimen Handling 39 venetoclax 38 Paclitaxel 38 Nivolumab 38 Magnetic Resonance Spectroscopy 37 Cisplatin 36 Dexamethasone 35 Biopsy 32 Docetaxel 30 atezolizumab 29 Temozolomide 28 Capecitabine 25 toripalimab 24 Oxaliplatin 24 Irinotecan 24 Fluorouracil 24 Azacitidine 24 abemaciclib 23 Pemetrexed 23 Fulvestrant 22 Rituximab 21 fludarabine phosphate 19 Cetuximab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07002320 2026-04-15

ASpiRE

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡